Protalix BioTherapeutics, Inc. (PLX)
USD 2.24
(-6.28%)
USD 2.24
(-6.28%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.64 Million USD | -83.82% |
| 2022 | 16.36 Million USD | 396.7% |
| 2021 | -5.51 Million USD | -111.95% |
| 2020 | 46.13 Million USD | 6.96% |
| 2019 | 43.13 Million USD | 324.62% |
| 2018 | 10.15 Million USD | 891.02% |
| 2017 | 1.02 Million USD | -92.8% |
| 2016 | 14.23 Million USD | 432.83% |
| 2015 | -4.27 Million USD | -133.69% |
| 2014 | 12.69 Million USD | 165.62% |
| 2013 | -19.35 Million USD | 62.81% |
| 2012 | -52.03 Million USD | -92.72% |
| 2011 | -27 Million USD | 24.79% |
| 2010 | -35.9 Million USD | 55.82% |
| 2009 | -81.26 Million USD | -90.78% |
| 2008 | -42.59 Million USD | 31.09% |
| 2007 | -61.81 Million USD | -301.96% |
| 2006 | -15.37 Million USD | -1460.84% |
| 2005 | -985.23 Thousand USD | -74.78% |
| 2004 | -563.71 Thousand USD | -214.08% |
| 2003 | -179.47 Thousand USD | 77.78% |
| 2002 | -807.63 Thousand USD | 11.79% |
| 2001 | -915.63 Thousand USD | -134.33% |
| 2000 | -390.73 Thousand USD | -11.75% |
| 1999 | -349.64 Thousand USD | 71.47% |
| 1998 | -1.22 Million USD | -123.63% |
| 1997 | -547.93 Thousand USD | 28.28% |
| 1996 | -763.96 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -837 Thousand USD | -131.62% |
| 2024 Q2 | 2.75 Million USD | 428.91% |
| 2023 Q4 | 2.64 Million USD | -52.72% |
| 2023 FY | 2.64 Million USD | -83.82% |
| 2023 Q1 | 532 Thousand USD | -96.75% |
| 2023 Q2 | -22.21 Million USD | -4275.75% |
| 2023 Q3 | 5.59 Million USD | 125.2% |
| 2022 Q4 | 16.36 Million USD | -27.02% |
| 2022 Q2 | 20.51 Million USD | 24.27% |
| 2022 Q3 | 22.42 Million USD | 9.28% |
| 2022 Q1 | 16.51 Million USD | 399.37% |
| 2022 FY | 16.36 Million USD | 396.7% |
| 2021 Q3 | 26.08 Million USD | -7.53% |
| 2021 Q1 | 41.24 Million USD | -10.59% |
| 2021 FY | -5.51 Million USD | -111.95% |
| 2021 Q4 | -5.51 Million USD | -121.14% |
| 2021 Q2 | 28.21 Million USD | -31.6% |
| 2020 Q4 | 46.13 Million USD | -7.74% |
| 2020 FY | 46.13 Million USD | 6.96% |
| 2020 Q1 | 47.51 Million USD | 10.17% |
| 2020 Q2 | 57.75 Million USD | 21.53% |
| 2020 Q3 | 50 Million USD | -13.41% |
| 2019 Q2 | 30.09 Million USD | 25.09% |
| 2019 Q3 | 34.47 Million USD | 14.54% |
| 2019 Q4 | 43.13 Million USD | 25.11% |
| 2019 Q1 | 24.06 Million USD | 136.88% |
| 2019 FY | 43.13 Million USD | 324.62% |
| 2018 Q3 | 5.45 Million USD | -70.39% |
| 2018 FY | 10.15 Million USD | 891.02% |
| 2018 Q4 | 10.15 Million USD | 86.32% |
| 2018 Q2 | 18.41 Million USD | 71.8% |
| 2018 Q1 | 10.71 Million USD | 945.76% |
| 2017 FY | 1.02 Million USD | -92.8% |
| 2017 Q3 | 30.35 Million USD | 30.01% |
| 2017 Q1 | 69.48 Million USD | 388.15% |
| 2017 Q4 | 1.02 Million USD | -96.62% |
| 2017 Q2 | 23.34 Million USD | -66.4% |
| 2016 FY | 14.23 Million USD | 432.83% |
| 2016 Q1 | 5.53 Million USD | 229.48% |
| 2016 Q2 | 17.69 Million USD | 219.47% |
| 2016 Q3 | 21.11 Million USD | 19.32% |
| 2016 Q4 | 14.23 Million USD | -32.57% |
| 2015 Q4 | -4.27 Million USD | -112.76% |
| 2015 Q3 | 33.52 Million USD | 37.22% |
| 2015 FY | -4.27 Million USD | -133.69% |
| 2015 Q1 | 19.6 Million USD | 54.43% |
| 2015 Q2 | 24.43 Million USD | 24.6% |
| 2014 FY | 12.69 Million USD | 165.62% |
| 2014 Q1 | -10.53 Million USD | 45.53% |
| 2014 Q4 | 12.69 Million USD | 80.3% |
| 2014 Q3 | 7.04 Million USD | 281.07% |
| 2014 Q2 | -3.88 Million USD | 63.1% |
| 2013 Q4 | -19.35 Million USD | 20.87% |
| 2013 Q3 | -24.45 Million USD | 26.18% |
| 2013 Q1 | -41.87 Million USD | 19.53% |
| 2013 Q2 | -33.12 Million USD | 20.88% |
| 2013 FY | -19.35 Million USD | 62.81% |
| 2012 Q4 | -52.03 Million USD | -3.62% |
| 2012 FY | -52.03 Million USD | -92.72% |
| 2012 Q3 | -50.21 Million USD | 8.03% |
| 2012 Q2 | -54.6 Million USD | -19.72% |
| 2012 Q1 | -45.6 Million USD | -68.9% |
| 2011 Q4 | -27 Million USD | 21.88% |
| 2011 FY | -27 Million USD | 24.79% |
| 2011 Q1 | -50.22 Million USD | -39.91% |
| 2011 Q2 | -39.6 Million USD | 21.15% |
| 2011 Q3 | -34.56 Million USD | 12.72% |
| 2010 Q2 | -54.96 Million USD | 20.76% |
| 2010 Q3 | -44.4 Million USD | 19.21% |
| 2010 FY | -35.9 Million USD | 55.82% |
| 2010 Q4 | -35.9 Million USD | 19.15% |
| 2010 Q1 | -69.36 Million USD | 14.65% |
| 2009 Q1 | -34.91 Million USD | 18.04% |
| 2009 Q4 | -81.26 Million USD | -259.43% |
| 2009 FY | -81.26 Million USD | -90.78% |
| 2009 Q3 | -22.61 Million USD | 22.39% |
| 2009 Q2 | -29.13 Million USD | 16.55% |
| 2008 Q2 | -53.36 Million USD | 7.65% |
| 2008 Q1 | -57.78 Million USD | 6.52% |
| 2008 FY | -42.59 Million USD | 31.09% |
| 2008 Q4 | -42.59 Million USD | 7.49% |
| 2008 Q3 | -46.04 Million USD | 13.71% |
| 2007 Q2 | -22.48 Million USD | 9.67% |
| 2007 Q4 | -61.81 Million USD | -202.41% |
| 2007 FY | -61.81 Million USD | -301.96% |
| 2007 Q1 | -24.89 Million USD | -61.89% |
| 2007 Q3 | -20.44 Million USD | 9.11% |
| 2006 Q4 | -15.37 Million USD | -1762.42% |
| 2006 Q3 | -825.7 Thousand USD | 10.72% |
| 2006 Q2 | -924.87 Thousand USD | 0.74% |
| 2006 Q1 | -931.72 Thousand USD | 5.43% |
| 2006 FY | -15.37 Million USD | -1460.84% |
| 2005 FY | -985.23 Thousand USD | -74.78% |
| 2005 Q4 | -985.23 Thousand USD | -99.53% |
| 2005 Q3 | -493.78 Thousand USD | 4.15% |
| 2005 Q2 | -515.15 Thousand USD | 3.38% |
| 2005 Q1 | -533.19 Thousand USD | 5.41% |
| 2004 FY | -563.71 Thousand USD | -214.08% |
| 2004 Q3 | -579.06 Thousand USD | 6.92% |
| 2004 Q2 | -622.14 Thousand USD | -449.31% |
| 2004 Q1 | -113.25 Thousand USD | 36.9% |
| 2004 Q4 | -563.71 Thousand USD | 2.65% |
| 2003 Q1 | -819.36 Thousand USD | -1.45% |
| 2003 FY | -179.47 Thousand USD | 77.78% |
| 2003 Q4 | -179.47 Thousand USD | 76.26% |
| 2003 Q3 | -756.05 Thousand USD | 2.64% |
| 2003 Q2 | -776.58 Thousand USD | 5.22% |
| 2002 Q4 | -807.63 Thousand USD | 1.94% |
| 2002 FY | -807.63 Thousand USD | 11.79% |
| 2002 Q1 | -862.76 Thousand USD | 5.77% |
| 2002 Q2 | -836.79 Thousand USD | 3.01% |
| 2002 Q3 | -823.6 Thousand USD | 1.58% |
| 2001 Q3 | -932.84 Thousand USD | 1.41% |
| 2001 FY | -915.63 Thousand USD | -134.33% |
| 2001 Q1 | -336.17 Thousand USD | 13.96% |
| 2001 Q4 | -915.63 Thousand USD | 1.84% |
| 2001 Q2 | -946.19 Thousand USD | -181.46% |
| 2000 FY | -390.73 Thousand USD | -11.75% |
| 2000 Q1 | -317.72 Thousand USD | 9.13% |
| 2000 Q2 | -374.19 Thousand USD | -17.77% |
| 2000 Q4 | -390.73 Thousand USD | -9.42% |
| 2000 Q3 | -357.08 Thousand USD | 4.57% |
| 1999 FY | -349.64 Thousand USD | 71.47% |
| 1999 Q1 | -696.95 Thousand USD | 41.92% |
| 1999 Q3 | -1.21 Million USD | -30.7% |
| 1999 Q4 | -349.64 Thousand USD | 71.27% |
| 1999 Q2 | -931.24 Thousand USD | -33.62% |
| 1998 Q4 | -1.2 Million USD | 29.41% |
| 1998 Q1 | -500 Thousand USD | -225.0% |
| 1998 Q2 | -2.7 Million USD | -440.0% |
| 1998 FY | -1.22 Million USD | -123.63% |
| 1998 Q3 | -1.7 Million USD | 37.04% |
| 1997 Q3 | -700 Thousand USD | 0.0% |
| 1997 Q1 | -700 Thousand USD | 0.0% |
| 1997 Q4 | 400 Thousand USD | 157.14% |
| 1997 FY | -547.93 Thousand USD | 28.28% |
| 1997 Q2 | -700 Thousand USD | 0.0% |
| 1996 FY | -763.96 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | 153.54% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 169.384% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 97.523% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 103.55% |
| Azitra, Inc. | -910.04 Thousand USD | 390.866% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | 162.459% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | -125.797% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 48.969% |
| CEL-SCI Corporation | 9.42 Million USD | 71.918% |
| iBio, Inc. | -9.75 Million USD | 127.149% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 108.147% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | 137.017% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | 306.635% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -503.726% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | 778.718% |
| NanoViricides, Inc. | -4.79 Million USD | 155.171% |
| Oragenics, Inc. | -3.17 Million USD | 183.481% |
| BiomX Inc. | -772 Thousand USD | 442.876% |
| BiomX Inc. | -772 Thousand USD | 442.876% |
| Palatin Technologies, Inc. | -8.93 Million USD | 129.618% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 80.898% |
| Theriva Biologics, Inc. | -21.02 Million USD | 112.591% |